Insulin Resistance 胰島素阻抗

COND-insulin-resistance

5

interventions reviewed

B

top legacy tier

1

counter-evidence

B Preliminary 1

Published with Warning ⚠️ Moderate market risk

C Weak 3

Bitter Melon Peptide (mcIRBP-19 / MAP30)

苦瓜胜肽（山苦瓜胜肽 / mcIRBP-19）

Disputed ⚠️ Moderate market risk

鉻（三價鉻）

Published ⚠️ Moderate market risk

Nicotinamide Mononucleotide (NMN)

菸鹼醯胺單核苷酸 (NMN)

Published with Warning 🚨 High market risk

D Counter-evidence 1

Nicotinamide Riboside

菸鹼醯胺核糖

Taiwan Regulatory Restriction ✨ Low market risk